Studies on lymphoid tissue from HIV-infected individuals: Implications for the design of therapeutic strategies

Springer Seminars in Immunopathology

Volumn 18, Issue 3, 1997, Pages 305-322

  Cohen, Oren J ^a   Pantaleo, Giuseppe ^a   Lam, Gordon K ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE BIOPSY; LYMPHOCYTE; LYMPHOID TISSUE; PATHOGENESIS; PRIORITY JOURNAL; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; LYMPHOID TISSUE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRUS REPLICATION;

EID: 0031048050     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00813500     Document Type: Article

References (67)

1. Fauci A, Schnittman S, Poli G, Koenig S, Pantaleo G (1991) Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 114:678
2. Bagnarelli P, Menzo S, Valenza A, et al (1992) Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 66:7328
3. Piatak M, Saag M, Yang L, et al (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749
4. Pantaleo G, Graziosi C, Butini L, et al (1991) Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 88:9838
5. Pantaleo G, Graziosi C, Demarest JF, et al (1993) HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355
6. Embretson J, Zupancic M, Ribas J, et al (1993) Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359
7. Wei X, Ghosh SK, Taylor ME, et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123
9. Cohen OJ, Pantaleo G, Holodniy M, et al (1995) Decreased HIV-1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995, 92:6017
10. Mondino A, Khoruts A, Jenkins M (1996) The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 93:2245
11. Pantaleo G, Graziosi C, Demarest JF, Cohen O, Vaccarezza M, Gantt K, et al (1994) Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 140:105
12. Koup RA, Safrit JT, Cao Y, et al (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650
13. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103
14. Joling P, Bakker L, Van Strijp J, et al (1993) Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 150:1065
15. + T-helper cells. Am J Pathol 140:15
16. Rácz P, Tenner-Rácz K, Kahl C, et al (1986) Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy 37:81
17. Turner R, Levine A, Gill P, Parker J, Meyer P (1987) Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. Am J Surg Pathol 11:625
18. Sei S, Akiyoshi H, Bernard J, et al (1996) Dynamics of virus versus host interaction in children with human immunodeficiency virus type 1 infection. J Infect Dis 173:1485
19. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377:740
20. Bukrinsky M, Stanwick T, Dempsey M, Stevenson M (1991) Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423
21. Ascher M, Sheppard H (1988) AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 73:165
22. Bass H, Nishanian P, Hardy W, et al (1992) Immune changes in HIV infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol 64:63
23. Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP (1991) The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 4:704
24. Fauci A (1988) The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 239:617
25. Fauci A (1993) Multifactorial nature of human immunodeficiency virus diseases: implications for therapy. Science 262:1011
26. Rosenberg Z, Fauci A (1989) Induction of expression of HIV in latently or chronically infected cells. AIDS Res Hum Retroviruses 5:1
27. Poli G, Fauci AS (1993) Cytokine modulation of HIV expression. Semin Immunol 5:165
28. Graziosi C, Pantaleo G, Gantt KR, et al (1994) Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248
29. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213
30. Westermann J, Persin S, Matyas J, Meide P van der, Pabst R (1994) Migration of so-called naive and memory T lymphocytes from blood to lymph in the rat. The influence of IFN-gamma on the circulation pattern. J Immunol 152:1744
31. Sprenger R, Toellner K, Schmelz C, et al (1995) Follicular dendritic cells productively infected with immunodeficiency viruses transmit infection to T cells. Med Microbiol Immunol 184:129
32. Schmitz J, Lunzen J van, Tenner-Racz K, et al (1994) Follicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. J Immunol 153:1352
33. Hivroz C, Mazerolles F, Soula M, et al (1993) Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56lck in human CD4 T lymphocytes. Eur J Immunol 23:600
34. Goldman F, Jensen W, Johnson G, Heasley L, Cambier J (1994) gp120 ligation of CD4 induces p56lck activation and TCR desensitization independent of TCR tyrosine phosphorylation. J Immunol 153:2905
35. Banda N, Bernier J, Kurahara D, et al (1992) Cross-linking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 176:1099
36. Li C, Friedman D, Wang C, Metelev V, Pardee A (1995) Induction of apoptosis in uninfected lymphocytes by HIV-1 tat protein. Science 268:429
37. Westendorp M, Frank R, Ochsenbauer C, et al (1995) Sensitization of T cells to CD95-mediated apoptosis by HIV-1 tat and gp120. Nature 375:497
38. Howcroft T, Strebel K, Martin M, Singer D (1993) Repression of MHC class I gene promoter activity by two-exon tat of HIV. Science 260:1320
39. Dawson V, Dawson T, Uhl G, Snyder S (1993) Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 90:3256
40. Pietraforte D, Tritarelli E, Testa U, Minetti M (1994) gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages. J Leukoc Biol 55:175
41. Bukrinsky M, Nottet H, Schmidtmayerova H, et al (1995) Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med 181:735
42. Weeks B, Klotman M, Holloway E, Stetler-Stevenson W, Kleinman H, Klotman P (1993) HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase. AIDS Res Hum Retroviruses 9:513
43. Lafrenie R, Wahl L, Epstein J, Hewlett I, Yamada K, Dhawan S (1996) HIV-1 tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. J Immunol 156:1638
44. Cohen O, Pantaleo G, Holodniy M, et al (1996) Antiretroviral monotherapy in early human immunodeficiency virus disease has no detectable effect on viral load in peripheral blood and lymph nodes. J Infect Dis 173:849
45. Biberfeld P, Chayt K, Marselle L, Biberfeld G, Gallo R, Harper M (1986) HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am J Pathol 125:436
46. Fox C, Tenner-Rácz K, Rácz P, Firpo A, Pizzo P, Fauci A (1991) Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 164:1051
47. Burke AP, Anderson D, Mannan P, et al (1994) Systemic lymphadenopathic histology in human immunodeficiency virus-1-seropositive drug addicts without apparent acquired immunodeficiency syndrome. Hum Pathol 25:248
48. Fischl M, Richman D, Grieco M, et al (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:185
49. Fischl M, Richman D, Hansen N, et al (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 112:727
50. -positive cells per cubic millimeter. N Engl J Med 322:941
51. Volberding P, Lagakos S, Grimes J, et al (1994) The duration of zidovudine benefit in persons with asymptomatic HIV infection. J Am Med Assoc 272:437
52. Vella S, Giuliano M, Dally L, et al (1994) Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. J Acquir Immune Defic Syndr 7:31
53. + cell counts greater than 400 per cubic millimeter. N Engl J Med 329:297
54. Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343:871
55. Volberding P, Lagakos S, Grimes J, et al (1995) A comparison of immediate with deferred zidovudine therapy for asyptomatic HIV- infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 333:401
56. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 118:674
57. Armstrong J, Horne R (1984) Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy. Lancet II:370
58. Baroni C, Pezzella F, Mirolo M, Ruco L, Rossi G (1986) Immunohistochemical demonstration of p24 HTLV-III major core protein in different cell types within lymph nodes from patients with lymphadenopathy syndrome (LAS). Histopathology 10:5
59. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O (1996) Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 174:404
60. Mellors J Jr, CR, Gupta P, White R, Todd J, Kingsley L (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167
61. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 334:426
62. Sei S, Kleiner D, Kopp J, et al (1994) Quantitative analysis of viral burden in tissues from adults and children with symptomatic human immunodeficiency virus type 1 infection assessed by polymerase chain reaction. J Infect Dis 170:325
63. Perrin L, Yerly S, Lazzarin A, et al (1996) Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZT-ddI. Eleventh International Conference on AIDS, Vancouver, 1996. We.B. 532
64. Markowitz M, Cao Y, Hurley A, et al (1996) Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. Eleventh International Conference on AIDS, Vancouver, 1996. Th.B. 933
65. Saimot AG, Simon F, Landman R, et al (1996) A triple nucleoside analogue combination in four patients with primary HIV-1 infections: towards complete virological remissions? Eleventh International Conference on AIDS, Vancouver, 1996. Mo.B. 1332
66. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al (1995) A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333:408
67. Perelson AS, Essungen P, Markowitz M, Ho DD (1996) How long should treatment be given if we had an antiretroviral regimen that completely blocks HIV replication? Eleventh International Conference on AIDS, Vancouver, 1996. Th.B. 930